CA3146811A1 - Methods for alleviating pterygium-associated worry about eye appearance - Google Patents

Methods for alleviating pterygium-associated worry about eye appearance Download PDF

Info

Publication number
CA3146811A1
CA3146811A1 CA3146811A CA3146811A CA3146811A1 CA 3146811 A1 CA3146811 A1 CA 3146811A1 CA 3146811 A CA3146811 A CA 3146811A CA 3146811 A CA3146811 A CA 3146811A CA 3146811 A1 CA3146811 A1 CA 3146811A1
Authority
CA
Canada
Prior art keywords
symptoms
patient reported
patient
reported signs
reducing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3146811A
Other languages
English (en)
French (fr)
Inventor
Jinsong Ni
Scott Whitcup
Rong Yang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cloudbreak Therapeutics LLC
Original Assignee
Cloudbreak Therapeutics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cloudbreak Therapeutics LLC filed Critical Cloudbreak Therapeutics LLC
Publication of CA3146811A1 publication Critical patent/CA3146811A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Eye Examination Apparatus (AREA)
CA3146811A 2019-09-10 2020-09-10 Methods for alleviating pterygium-associated worry about eye appearance Pending CA3146811A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962898401P 2019-09-10 2019-09-10
US62/898,401 2019-09-10
PCT/US2020/050150 WO2021050692A2 (en) 2019-09-10 2020-09-10 Methods for alleviating pterygium-associated worry about eye appearance

Publications (1)

Publication Number Publication Date
CA3146811A1 true CA3146811A1 (en) 2021-03-18

Family

ID=74870040

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3146811A Pending CA3146811A1 (en) 2019-09-10 2020-09-10 Methods for alleviating pterygium-associated worry about eye appearance

Country Status (10)

Country Link
US (1) US20220331310A1 (enExample)
EP (1) EP4027997A4 (enExample)
JP (1) JP2022547401A (enExample)
KR (1) KR20220061147A (enExample)
CN (1) CN114340618A (enExample)
AU (2) AU2020346812A1 (enExample)
BR (1) BR112021026662A2 (enExample)
CA (1) CA3146811A1 (enExample)
MX (1) MX2022000468A (enExample)
WO (1) WO2021050692A2 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20260025887A (ko) 2015-06-06 2026-02-24 클라우드브레이크 테라퓨틱스, 엘엘씨 익상편을 치료하기 위한 조성물 및 방법
AU2017274195B2 (en) 2016-06-02 2022-04-07 Ads Therapeutics Llc Compositions and methods of using nintedanib for improving glaucoma surgery success

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100185564A1 (en) * 2009-01-21 2010-07-22 Mccormick & Company, Inc. Method and questionnaire for measuring consumer emotions associated with products
HK1204563A1 (en) * 2012-06-25 2015-11-27 Bayer Healthcare Llc Topical ophthalmological pharmaceutical composition containing pazopanib
US8747852B1 (en) * 2012-12-28 2014-06-10 Randal Tanh Hoang Pham Methods of treating pterygium
KR20260025887A (ko) * 2015-06-06 2026-02-24 클라우드브레이크 테라퓨틱스, 엘엘씨 익상편을 치료하기 위한 조성물 및 방법
PE20180252A1 (es) * 2015-06-09 2018-02-02 Bayer Pharma AG Moduladores alostericos positivos del receptor muscarinico m2
TWI700085B (zh) * 2015-06-22 2020-08-01 新源生物科技股份有限公司 酪胺酸激酶抑制劑之眼用調配物的用途
CN108295072A (zh) * 2015-12-09 2018-07-20 瑞阳(苏州)生物科技有限公司 尼达尼布防治眼部疾病的用途
CN108602879A (zh) * 2016-02-04 2018-09-28 倪劲松 用于治疗疾病的抗体-药物协同作用技术
AU2017274195B2 (en) * 2016-06-02 2022-04-07 Ads Therapeutics Llc Compositions and methods of using nintedanib for improving glaucoma surgery success
US11278546B2 (en) * 2016-07-22 2022-03-22 Aiviva Biopharma, Inc. Multikinase inhibitors and uses in ocular fibrosis
US11510931B2 (en) * 2016-09-28 2022-11-29 Medicon Pharmaceuticals, Inc. Compositions and methods for treating ophthalmic conditions
CN110072849A (zh) * 2017-03-14 2019-07-30 新源生物科技股份有限公司 3-z-[1-(4-(n-((4-甲基-哌嗪-1-基)-甲羰基)-n-甲基-氨基)-苯氨基)-1-苯基-亚甲基]-6-甲氧羰基-2-吲哚满酮的晶型
AU2019272871B2 (en) * 2018-05-25 2025-02-27 Ads Therapeutics Llc A composition for treating ocular hyperemia and a method for treating ocular hyperemia with the same

Also Published As

Publication number Publication date
AU2020346812A1 (en) 2022-01-27
CN114340618A (zh) 2022-04-12
AU2026202351A1 (en) 2026-04-16
EP4027997A2 (en) 2022-07-20
BR112021026662A2 (pt) 2022-04-12
WO2021050692A3 (en) 2021-05-14
EP4027997A4 (en) 2023-10-11
JP2022547401A (ja) 2022-11-14
US20220331310A1 (en) 2022-10-20
KR20220061147A (ko) 2022-05-12
WO2021050692A2 (en) 2021-03-18
MX2022000468A (es) 2022-02-03

Similar Documents

Publication Publication Date Title
US10149820B2 (en) Compositions and methods for treating pterygium
Talamo et al. Modulation of corneal wound healing after excimer laser keratomileusis using topical mitomycin C and steroids
Iqbal et al. Standard cross‐linking versus photorefractive keratectomy combined with accelerated cross‐linking for keratoconus management: a comparative study
EP3886858B1 (en) Compounds for treatment of eye diseases associated with excessive vascularisation
AU2026202351A1 (en) Methods for alleviating pterygium-associated worry about eye appearance
Chanbour et al. Corneal cross-linking for keratoconus and post-LASIK ectasia and failure rate: a 3 years follow-up study
JP2024516003A (ja) 糖尿病網膜症および関連する状態を治療するための方法および組成物
US20240398736A1 (en) Eyedrops for Treating Scleral Thinning and Screening Method for Therapeutic Agent of Scleral Thinning
Hass et al. Comparison between pilocarpine and timolol on diurnal pressures in open-angle glaucoma
JP2022547401A5 (enExample)
HK40068230A (en) Methods for alleviating pterygium-associated worry about eye appearance
Gillies et al. Topical interferon alpha 2b for corneal haze after excimer laser photorefractive keratectomy
Varshney et al. Ropivacaine versus bupivacaine-lignocaine mixture in peribulbar block-A comparative study
Humayun et al. Mechanical epithelial debridement< em> versus transepithelial phototherapeutic keratectomy followed by accelerated corneal collagen crosslinking for progressive keratoconus
Subasi et al. Macular safety and outcomes of accelerated cross-linking with a 7.2 J/cm² energy dose in keratoconus: A prospective case series
HK40061312A (en) Compounds for treatment of eye diseases associated with excessive vascularisation
HK40061312B (en) Compounds for treatment of eye diseases associated with excessive vascularisation
Prakash Chlorpromazine-Induced Cataract and Corneal Pigmentation
HK40101374A (en) Compositions and methods for treating pterygium
Parida et al. Comparative clinical efficacy of bepotastine besilate versus olopatadine Hcl in seasonal allergic conjuctivitis
Kronemyer Surgical treatments range from cross-linking to keratoplasty when keratoconus progresses.
SUTPHIN Corneal Crosslinking with Riboflavin and Ultraviolet A. Part II. Clinical Indications and Results
Fortes et al. The action of topic diluted anesthetic and mitomycin on the symptomatology and corneal re-epithelialization at postoperative photorefractive keratectomy
Bekibele et al. Release date: 18 March 2016; Expiration date: 18 March 2017
HK1253895B (en) Compositions and methods for treating pterygium

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220901

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240827

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240827

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240827

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20241216

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250414

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250415

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250702

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250702

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250718

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250718

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20260402